Kolon Life Science Inc. (102940.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	211.4B	209.0B	161.4B	124.6B	161.6B
Cost of Revenue	156.0B	155.5B	144.5B	112.2B	124.4B
Gross Profit	55.5B	53.4B	16.9B	12.4B	37.1B
Operating Expenses
R&D Expense	13.5B	13.9B	16.4B	14.9B	13.6B
SG&A Expense	16.1B	12.7B	12.2B	11.5B	11.8B
General & Admin Expense	6.7B	8.6B	8.1B	8.3B	8.5B
Selling & Marketing Expense	3.0B	4.0B	4.0B	3.2B	3.3B
Other Expenses	(4.2B)	12.0B	10.4B	10.2B	9.2B
Total Operating Expenses	22.1B	38.6B	39.0B	36.5B	34.5B
Cost and Expenses	175.6B	194.2B	183.5B	148.7B	158.9B
Operating Income (EBIT)	35.8B	14.8B	(22.1B)	(24.1B)	2.6B
Non-Operating
Interest Income	88.8M	94.4M	135.0M	168.6M	114.1M
Interest Expense	6.6B	7.8B	7.4B	5.9B	3.7B
Net Interest Income	(6.6B)	(7.7B)	(7.3B)	(5.7B)	(3.6B)
Other Non-Op Income/Expense	(649.0M)	11.0B	(71.0B)	(9.5B)	1.5B
Non-Operating Income (excl Interest)	(5.8B)	—	63.6B	3.6B	1.2B
EBT (Pre-Tax Income)	35.2B	25.8B	(93.1B)	(33.6B)	4.1B
Income Tax Expense	527.0M	795.8M	—	1.3M	107.9M
Bottom Line
Net Income	34.6B	24.8B	(93.1B)	(30.7B)	2.1B
Earnings from Cont. Ops	34.6B	24.8B	(93.1B)	(33.6B)	4.0B
Earnings from Discont. Ops	—	—	—	2.9B	(1.9B)
Bottom Line Net Income	34.6B	24.8B	(93.1B)	(30.7B)	2.1B
Per Share
Basic EPS	₩2,747	₩2,001	(₩7,517)	(₩2,692)	₩187
Diluted EPS	₩2,241	₩1,824	(₩7,517)	(₩2,431)	₩163
Revenue Per Share	₩16,152	₩16,191	₩13,033	₩10,920	₩14,164
Shares
Basic Shares Outstanding	13.1M	12.9M	12.4M	11.4M	11.4M
Diluted Shares Outstanding	13.1M	12.9M	12.4M	12.6M	13.1M
Profitability Metrics
EBITDA	36.1B	25.5B	(76.8B)	(18.9B)	12.1B
D&A	11.2B	10.7B	8.9B	8.8B	9.5B
EBIT	25.1B	14.8B	(85.7B)	(27.7B)	2.6B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026